US EditionPrecision Oncology Cost-Effectiveness: Balancing Innovation, Policy, and Patient Realities
Summary by Daily-remedy.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Precision Oncology Cost-Effectiveness: Balancing Innovation, Policy, and Patient Realities
A single infusion of CAR-T cells can redefine a cancer patient’s prognosis while simultaneously igniting scrutiny over a $475,000 price tag. The June 2025 approval of Bristol-Myers Squibb’s cilta-cabtagene autoleucel for multiple myeloma has sharpened debates over how health systems can afford these curative promises without forsaking equity or sustainability (Reuters). At the same time, tumor-agnostic agents—drugs targeting rare genomic alterat…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
